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SUMMARY - Current concepts of endoscopic treatment of gastroesophageal variceal hemorrhage
are discussed. There are two major endoscopic treatments of gastroesophageal varices: endoscopic
injection sclerotherapy (EIS) and endoscopic variceal ligation (EVL). EIS and EVL alone are equally
effective in controlling acute variceal bleeding, however, EVL is superior to EIS because it achieves
variceal obliteration faster and with a lower rate of complications and rebleeding. Considering com-
bined technique of EVL and EIS, it appears that initial EVL followed by long-term EIS on later
sessions, when banded varices have become smaller, probably is a wiser approach for safe and longlasting
variceal eradication. Histoacryl as a tissue glue is the only endoscopic treatment that has been proved
to be effective for gastric varices. The use of endoscopic clips alone in the treatment of varices re-
mains uncommon. The role of endoscopic ultrasound increases in the evaluation of portal hyperten-
sion, and it may gain a role in choosing an optimal treatment approach for individual patients.
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Introduction
Bleeding from gastroesophageal varices is a serious
complication of portal hypertension and the leading cause
of death in patients with portal hypertension, with a
mortality of up to 50% for the initial bleed and 30% for
subsequent bleeds1,2. It is a common cause of upper gas-
trointestinal hemorrhage, accounting for approximately
one third of diagnoses in individuals presenting with up-
per gastrointestinal bleeding.
Most cirrhotics eventually develop esophageal va-
rices3-5, the incidence being approximately 50% among all
cirrhotics. About one third of patients with esophageal
varices experience a variceal hemorrhage6,7. Identification
of risk factors for esophageal variceal hemorrhage is im-
portant because of high mortality of each bleeding epi-
sode. The risk of bleeding is related to the degree of por-
tal hypertension, variceal location (highest near the gas-
troesophageal junction), presence of red signs on the va-
rices on endoscopy, and liver failure. After gastroesoph-
ageal varices have started bleeding, the hemorrhage spon-
taneously stops in only 50% of cases8. Upon cessation of
active bleeding, the risk of rebleeding is high for approxi-
mately 6 weeks1. The risk of early rebleeding is greatest
within the first 48 hours, and about half of all early
rebleeding episodes occur within this time period. The
long-term course after an initial bleed is punctuated by
repeated episodes of variceal hemorrhage with its atten-
dant risks of exsanguination, hepatic encephalopathy, and
liver failure1,9,10. The risk of recurrent bleeding is related
to the liver failure severity, continued alcoholism, variceal
size, renal failure, and presence of hepatoma11. Approxi-
mately 70% of all untreated patients experience further
bleeding or die within one year of their initial bleeding12.
The risk of bleeding from gastric varices depends on
their location13,14: gastroesophageal varices along the
lesser curvature (GEV1) constitute more than 70% of
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gastric varices, but only 11% of GEV1 bleed. Isolated clus-
ter of varices in the gastric fundus (IGV1) constitute 8%
of all gastric varices and 80% of IGV1 bleed.
Endoscopic Injection Sclerotherapy
The treatment of variceal bleeding remained largely
expectant until the second half of the twentieth century.
The first report of endoscopic injection sclerotherapy
(EIS) for variceal bleeding was published in 1939 by
Crafoord and Frencker15. EIS remained unrecognized as
a therapeutic option until the advent of flexible endoscopy
in 1960s.
The goal of EIS is to inject the sclerosant that subse-
quently results in instantaneous coagulation necrosis and
induction of variceal thrombosis and scarring; it may be
performed by injection of the sclerosant directly into the
varix (intravariceal) to produce thrombosis, or adjacent to
the varix (paravariceal) to induce submucosal fibrosis and
obliteration of deeper perforating vessels. In practice, a
combination of both techniques may be utilized during
the same session. Techniques of sclerotherapy vary and are
operator-dependent. Several sclerosants have been em-
ployed in various combinations and volumes (Table 1).
EIS schedules have also varied considerably; more fre-
quent treatment intervals achieve more rapid variceal
obliteration, with greater mucosal ulceration16-18.
Table 1. Most commonly used sclerosants
· Sodium - tetradecyl sulfate




*Aethoxysclerol 1% (Kreussler Pharma, Germany), commonly used in
Croatia.
Complications of EIS are common and are occasion-
ally life threatening19. Fever, retrosternal discomfort and
dysphagia frequently occur acutely and usually resolve
within 48 hours. Injection-induced bleeding, postinjection
esophageal ulceration with delayed bleeding, and esoph-
ageal perforation may also occur. Dysphagia may occur
after EIS due to esophageal ulceration, dismotility, or
stricture formation that usually responds to dilatation.
Other potential complications include mediastinitis, pleu-
ral effusion, bronchoesophageal fistula, and ARDS. Bac-
teremia is common during EIS. To avoid these compli-
cations, the present policy is to use lower volumes of
sclerosant as varices decrease in size, in an attempt to re-
duce the extent of complications.
Endoscopic injection sclerotherapy has been widely
used in the emergency treatment of patients with actively
bleeding esophageal varices20,21. Even though the initial
bleed may be effectively controlled by sclerotherapy, the
risk of subsequent bleeding is substantial. There is a gen-
eral consensus that patients surviving a bleeding episode
should be treated to prevent rebleeding. The aim is to
achieve complete eradication of varices because it reduces
rebleeding and death from esophageal varices. Consider-
able evidence has supported the use of repeated EIS to
obliterate esophageal varices, thus to prevent further va-
riceal bleeding.
Despite the widespread use of EIS for the treatment
of bleeding esophageal varices and a plethora of published
studies, accurate long-term data detailing recurrence,
rebleeding rate after eradication, or the need of prolonged
endoscopic surveillance are scanty22,23. Despite the fact
that repeated EIS eradicated esophageal varices in most
patients, the most important limitation of long-term EIS
is the high incidence of rebleeding from residual varices
that occurred in 36% of patients24.
Endoscopic injection sclerotherapy in the treatment of gas-
tric varices
Bleeding from gastric varices continues to be a thera-
peutic challenge, due to their large size and extent. Sarin25
demonstrated that gastric variceal EIS is effective for junc-
tional, small size, lesser curvature varices associated with
esophageal varices (GOV1), but is not suitable for large,
major curvature varices (GOV2), and especially not for
isolated fundal varices. EIS as well as endoscopic band
ligation are unlikely to achieve complete obliteration of
extensive variceal conglomerates; necrosis caused by these
procedures may lead to fatal hemorrhage. Therefore, since
standard gastric variceal EIS has shown disastrous results,
such a treatment modality is not recommendable26.
Histoacryl is the only endoscopic treatment that has been
shown to be effective for gastric varices27,28.
Prophylactic endoscopic injection sclerotherapy
Prophylactic EIS has been extensively studied and it
is not recommended due to the high procedural compli-
cation rates, which may outweigh any benefits of the treat-
ment. Nonetheless, two randomized studies have been
published in which EIS and endoscopic variceal ligation
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were compared for prophylactic treatment of esophageal
varices. Surprisingly, both studies showed equal or better
results for EIS. Svoboda et al.29 conducted a study in the
Czech Republic and recommend EIS for primary preven-
tion of esophageal variceal bleeding; the mean number of
sessions required to achieve eradication was lower in the
ligation group than in the sclerotherapy group, but the two
endoscopic treatments were found to be equally effective
in reducing the incidence of initial bleeding. The recur-
rence of esophageal varices was higher in the ligation
group compared with the sclerotherapy group (31% vs.
11%; p=0.01). Total mortality was significantly lower in
the sclerotherapy group compared with the control group
(20% vs. 38%; p=0.04), but not in the ligation group com-
pared with controls (23% vs. 38%; p=0.10). Gotoh et al.30
performed a study in Japan, in which during 18-month
follow-up the incidence of bleeding was significantly
higher in patients treated with band ligation than in those
receiving EIS (20% vs. 0%). The authors explained these
findings by the higher rate of variceal recurrence in the
band ligation group (56% vs. 16%).
viewing field because it is attached to the tip of the en-
doscope, rendering visualization difficult, especially in a
setting of acute hemorrhage. During the last few years,
endoscopists all around the world have been focusing their
attention on ligating varices instead of injecting them.
Endoscopic band ligation
The results from several randomized, prospective tri-
als, which have directly compared EIS and endoscopic
band ligation (EBL) of esophageal varices, have shown
both techniques to be equally effective in arresting acute
esophageal variceal bleeding32,33 as well as in the preven-
tion of recurrent bleeding34-38 (Fig. 1). EBL has been
found to be superior to EIS for eradicating esophageal
varices more rapidly and with fewer complications34-39
(Table 2).
EBL has a significantly lower rate of development of
early complications and of bacteremia. Esophageal ulcers
are a necessary accompaniment of sclerotherapy as well as
of EBL, and would be seen universally following any in-
jury to the variceal wall. The frequency of development or
Table 2. Endoscopic injection sclerotherapy (EIS) vs. endoscopic band ligation (EBL)
No. of sessions
required Complication Obliteration of Recurrence of
(mean±SD) rate (%) varices (%)  varices (%)
Authors, year EIS EBL EIS EBL EIS EBL EIS EBL
Steigmann et al.34, 1992 4±2 5±2 22 2 56 55 50 33
Hou et al.35, 1995 4.6±1.6 3.5±1.6 22.4 4.5 79.1 86.6 28 40
Sarin et al.36, 1997 5.2±1.8 4.1±1.2 - - - - 6.4 21.3
Avgerinos et al.37, 1997 5.8±2.7 3.7±1.9 60 35 97.5 94.5 44 31
Baroncini et al.38, 1997 0.4±0.1 3.5±0.1 31 11 92.5 93 13 30
Hou et al.39, 1999 5.1±2.2 3.7±0.1 - - 86 88 - -
Endoscopic Variceal Ligation
Endoscopic variceal ligation (EVL) was initially in-
troduced by Steigmann in 1986, with the anticipation that
it would be approximately as efficacious as EIS, but as-
sociated with a lower incidence of complications31. EVL
achieves hemostasis by physical constriction of the varix.
It leads to local hemostasis and thrombosis with a vari-
able effect on the interconnecting perforating vessels. The
technique is easy to learn, and all current endoscope mod-
els can be used. It can be performed using bands and
miniloops. The banding device substantially reduces the
worsening of portal hypertensive gastropathy is higher af-
ter EIS than after EBL, probably due to the rapid occlu-
sion of varices and redistribution of blood flow in the gas-
tric microcirculation after EIS, whereas EBL does not cause
total occlusion of veins and some blood flow persists at the
gastroesophageal junction, which prevents the sudden and
near total redistribution of blood into the stomach.
Although EBL is a very attractive method because of
faster eradication and fewer complications, it has been
shown to be associated with a higher variceal recurrence
rate than EIS. So, EIS is superior to EBL as a long-term
treatment with a low variceal recurrence rate.
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EBL also seems to be a viable option for the treatment
of smaller gastric varices. In a study from Egypt, Shiha et
al.44 recorded a significantly lower rebleeding rate after
EBL compared to the one previously reported for patients
treated with EIS. However, large randomized and care-
fully designed trials with long-term follow-up are more
than necessary to confirm the value of EBL in the treat-
ment of gastric varices.
Endoscopic detachable miniloops
Detachable miniloops have been tested as an alterna-
tive to band ligation (Fig. 2). Sung and Chung40 consider
the method superior to band ligation for the ability to
place an unlimited number of loops with the probable cost
reduction and advantages of transparent cylinder for vi-
sualization. Furthermore, Hachisu et al.42 found that the
eradication rates were nonsignificantly higher when
miniloops were used. Although these studies have shown
an initially good response with the use of miniloops for
esophageal variceal ligation, the number of patients were
too small and the follow-up periods too short. Obviously,
further comparative studies are necessary to prove the
superiority of detachable loops over multiple ligation de-
vices, if already existing43.
Cipolletta et al.41 found a significant reduction in the
size of gastric varices in more than a half of patients when
miniloops were used, without early bleeding over 2 to 6
months. Therefore, loop ligation appears to be better
suited for gastric varices than band ligation. Anyway, ac-
cording to our own experience, the technical ‘simplicity’
of gastric variceal loop ligation is very questionable, and
more data are needed from a large number of patients and
with a longer follow-up to establish loop ligation as the
method of choice in gastric variceal ligation.
Combined endoscopic band ligation and injection sclero-
therapy
There are two types of combined EBL and EIS: syn-
chronous therapy as a combination of initial EBL and EIS
together, and sequential therapy as a combination of variceal
banding followed by sclerotherapy. The main idea of the
technique using a combination of EIS and EBL is to over-
come the limitations of the individual techniques and to
achieve: 1) faster variceal obliteration, 2) fewer endoscopy
sessions, 3) lesser complications, 4) lower recurrence rate,
and 5) cost - benefit advantage over either technique used
individually. Several clinical studies have attempted to ad-
dress one or more of these issues using two different ap-
proaches: (1) comparing EIS alone with a combination of
EBL and EIS; or (2) comparing EBL alone with a combi-
nation of EBL and EIS (Table 3).
Regarding the first two issues, i.e. whether the com-
bined technique of EBL and EIS (combined therapy) can
achieve faster obliteration of varices with fewer endoscopy
sessions as compared with EBL alone, Laine et al.45 and
Saeed et al.46 observed the opposite: combined therapy
significantly increased the number of endoscopy sessions
and the time required for variceal obliteration. Similar
observations have been reported by Bhargava et al.47, Lo
et al.48, and Masumoto et al.49, and have once again been
reaffirmed in the study of Al Traif et al.50
Regarding the third issue, the frequency and sever-
ity of complications using a combined technique, nearly
all available studies suggest that the frequency of com-
plications was higher in patients treated with combina-
tion therapy. Saeed et al.46 observed that deep ulcers were
significantly more common and in fact led to more fre-
quent ulcer-related bleeding episodes in the combination
treated patients than in those treated with band ligation.
Table 3. Endoscopic band ligation (EBL) vs. combination of endoscopic band ligation plus endoscopic injection sclero-
therapy (EIS)
No. of sessions
required Complication Obliteration Recurrence
(mean±SD) rate (%) of varices (%) of varices (%)
Authors, year EBL EBL+EIS EBL EBL+EIS EBL EBL+EIS EBL EBL+EIS
Saeed et al.46, 1997 3.3±0.4 4.1±0.6 25 65 64 54.5 16 23
Laine et al.45, 1996 2.7±0.4 4.9±0.6 10 29 - - - -
Lo et al.48, 1998 3.7±0.9 3.4±1.1 - - 91 97 43 14
Bhargava et al.47, 1997 4.3±1.8 5.9±2.3 40 60 24 87 - -
Masumoto et al.49, 1999 3.5±1.1 2.3±0.5 31 44 84 81 72 22.1
Al Traif et al.50, 1999 3.6±0.1 3.8±0.5 16 20 81 86 6 21
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Similar observations have also been reported by Laine et
al.45
The fourth issue, the rate of variceal recurrence after
initial obliteration, does not raise concern in the beginning
when early variceal obliteration is the main aim. Never-
theless, it assumes great importance during the follow-up
period. High recurrence rates following EBL could be
attributed to two main limitations of the technique: 1) the
inability to further ligate varices once they have become
small, and 2) inadequate obliteration of the perforating
veins that connect esophageal veins to paraesophageal
collaterals. It is only the issue of variceal recurrence where
the technique of EBL needs to be supplemented. Takeuchi
et al.51 and Masumoto et al.49 found that combined
therapy helped reduce the high complication rate of EIS
as well as the high recurrence rate after ligation therapy.
Considering the fifth issue, the cost - benefit advan-
tage of combined therapy over individual techniques, there
is only one published study evaluating the economic costs
of treating esophageal variceal hemorrhage using EIS and
EBL. Gralnek et al.52 evaluated direct costs of health care
with a possible increase in complications. Therefore, EVL
alone appears to be as yet the treatment of choice for
achieving variceal obliteration in patients who have bled
from varices in the past. However, the prohibitive cost of
disposable variceal banding equipment limits its univer-
sal use, particularly in developing countries with limited
fiscal and health care resources (Table 4). According to our
own experience, initial EVL followed by long-term EIS
on later sessions, when banded varices have become
smaller, may be a rational approach for safe and longlasting
variceal eradication.
Prophylactic endoscopic variceal ligation
Until the year 2000, prophylactic EVL was considered
a promising but not recommendable treatment for routine
clinical use for prophylaxis of initial variceal bleed-
ing29,30,53,54. Lo et al.53 found that EVL did not signifi-
cantly reduce the risk of initial bleeding episode from
esophageal varices in cirrhotic patients with a high risk of
bleeding from esophageal varices. Only a subgroup of
patients (Child-Pugh class B) had a reduced frequency of
Table 4. Cost items in Croatia
Cost (HRK)
Esophagogastroduodenoscopy 180.00
Sclerotherapy needles (0.4-0.7 mm; GIP MediGlobe, Germany)
· disposable 302.00
· nondisposable 1275.00
Polydocanol 1% (Aethoxysclerol 30 mL, Kreussler Pharma, Germany) 124.50
Histoacryl 0.5 mL (B/Braun, Germany) + Lipidodol 5 mL (Guerbet, Germany) 77.00 + 124.40
Saeed Ten Shooter Multi-Band Ligator (MBL-10; Wilson-Cook, USA) 2076.10
Quick-Loop for Variceal Ligation (HX-21L-1, MAJ-339; Olympus, Japan) 1567.70* + 1230.66
*Introducer (HX-21L-1), nondisposable. Cost items as per March 15, 2001 (1 DEM=3.95 HRK).
use and cost - effectiveness of EIS compared with EBL
in the prevention of variceal rebleeding and patient sur-
vival at 1-year follow-up. The median total direct cost
outcomes were similar in the two groups. EBL and EIS
had similar costs per variceal rebleeding prevented and cost
per survival. In the subgroup of active bleeders, EIS had
a substantially lower cost per survival. The authors con-
cluded that resource utilization was similar between the
treatment groups and that the choice of endoscopic
therapy for esophageal variceal hemorrhage must still rely
on clinical grounds.
In conclusion, there is clear evidence that simultaneous
addition of EIS hinders and delays obliteration of varices
the initial episode of esophageal variceal bleeding after
prophylactic EVL with a trend of reducing mortality from
variceal bleeding. Since the year 2000, prophylactic EVL
is becoming an acceptable option for the prevention of
initial bleeding from large esophageal varices, which has
been confirmed in several trials55: 1) meta-analysis review-
ing eight randomized controlled studies, which showed
reduced bleeding-related complications among EVL
groups compared with either untreated controls or those
receiving beta-blockers56; 2) prophylactic EVL was found
to be comparable to beta-blockers concerning prevention
of initial bleeding, serious adverse events, rate of liver
transplantation, and mean direct costs57; and 3) prophy-
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lactic EVL was associated with a lower rate of variceal
bleeding compared with untreated control subjects dur-
ing a median observation period of 14 months58. Anyway,




Cyanoacrylate glue injection for endoscopic treatment
of esophagogastric varices was first reported in 1986 by
Soehendra et al.67. For several years now, there has been
an increasingly widespread use of tissue adhesives or glues
in the treatment of bleeding esophagogastric varices to
achieve rapid hemostasis and to prevent rebleeding.
There are two chemical forms of cyanoacrylate: N-
butyl-2-cyanoacrylate (Histoacryl) and isobutyl-2-cy-
anoacrylate. Cyanoacrylate is a fast-solidifying substance,
appropriately used for occlusion of the varices. It physi-
cally occludes the lumen of the bleeding vessel immedi-
ately due to the chain polymerization reaction triggered
by contact between the cyanoacrylate and blood, which
transforms the cyanoacrylate from its original liquid form
into a solid substance. It is unlikely to cause inflamma-
tion and subsequent fibrosis of the esophageal wall, there-
fore it does not prevent the development of new varices.
It is a highly effective agent for immediate hemostasis as
well as for obliterating large varices.
To date, Histoacryl is the only endoscopic treatment
that has been proved to be effective for gastric vari-
ces27,28,59,60,63. After intravariceal application, Histoacryl
undergoes an instantaneous polymerization reaction and
hardens, thereby plugging the variceal lumen, enabling
rapid hemostasis of an actively bleeding varix, and prevents
rebleeding of the treated varix. However, reports on endo-
scopic treatment of esophageal varices using tissue glue are
not absolutely favorable. Two studies by Sung et al.61,62 have
not shown cyanoacrylate to be an attractive modality in
comparison with either EBL or EIS; initial hemostasis was
equal in all patient groups, but the early rebleeding and
complication rates were higher in the glue group than in
the ligation or sclerotherapy group. Fatal complications of
the use of cyanoacrylate, despite its instantaneous polymer-
ization process in the blood, have been reported in the lit-
erature: embolization of the solidified glue into the lungs64
and brain65, and progressive cardiac failure66. Such reports
support the view that its use should be limited to the treat-
ment of massive acute bleeding and huge gastroesophageal
varices, particularly those that cannot be successfully treated
with endoscopic ligation or injection sclerotherapy. Mucosal
ulcerations always occur after glue injection and allow the
solidified glue to extrude. It should therefore be regarded
as a normal consequence of glue injection rather than a
complication. Bleeding from such ulcers is only observed
if the varix has not been completely obliterated during the
initial injection. Today, Histoacryl is routinely diluted with
the oily contrast agent lipidolol in a ratio of 1:1.5, in order
to prevent premature solidification within or at the tip of
the injection catheter during injection, because lipidolol al-
ters the polymerization time of Histoacryl; and to permit
x-ray monitoring as lipidolol is radiopaque, thus enabling
evaluation of the Histoacryl extension toward the shunts
(Fig. 3).
Poly-N-acetyl glucosamine (p-GlcNAc) gel
The substance originates from marine microalgae, is
biocompatible, and has the effect of stimulating erythro-
cyte aggregation as well as vessel obliteration. In all cases,
hemostasis was possible after three or four injections (the
mean volume of the gel injected was 1.9 mL). Permanent
obliteration of the vessels was achieved in all cases after
one session. Over 90 days, the gel was gradually replaced
by connective tissue. Embolization to other organs, stric-
ture formation, and development of antibodies against the
substance were not observed. Kulling et al.68 suggest that
p-GlcNAc gel may be a potential alternative to cyanoacry-
late glue. The advantages of the gel may include its easier
application, without the risk of distant embolization as-
sociated with cyanoacrylate.
Endoscopic Clipping
Clipping of esophageal varices was originally demon-
strated in 1990 by Miyoshi et al.69 as another method
whereby esophageal varices were ligated by an endoscopi-
cally guided clipping device. Since the use of EIS for the
control of esophageal varices was widespread in Japan at
the beginning of the 1990s, in an effort to reduce the risk
of complications, Urita et al.70 developed a method that
combined endoscopically guided clipping and EIS: by first
clipping, then injecting sclerosant solution within and
beside the varix, it was retained for an extended period,
thus permitting the use of a smaller volume of sclerosant.
Comparing the combined method with EIS alone, the
authors found that fewer repeated endoscopic sessions and
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Fig. 3.
(a)  Esophageal varix obliterated with Histoacryl - Lipidodol mixture.
(b)  Obliterated varix is seen on the x-ray.
Fig. 1. Endoscopic Multi-Band Ligator (Wilson-Cook, USA) for
variceal ligation.
(a)  The varix is sucked into the cylinder.
(b)  The band-ligator in place.
Fig. 2. Endoscopic Detachable Miniloop (Olympus, Japan) for va-
riceal ligation.
(a)  The varix is sucked into the cylinder.
(b)  The detachable miniloop in place.
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lesser sclerosant solution volume were required, with a
higher success rate and fewer complications than with EIS
alone. However, the use of clips alone in the treatment of
varices remains uncommon. This method fails to achieve
permanent variceal eradication, and is therefore unlikely
to be cost-effective43.
Endosonography in the Treatment of Varices
The role of endoscopic ultrasound (EUS) has in-
creased in the evaluation of portal hypertension and
esophagogastric varices. Today, EUS can be used to inves-
tigate the pattern of varices and collaterals, and to moni-
tor therapeutic effect. EUS has a role in evaluating the risk
of recurrence and rebleeding after endoscopic treatment,
as confirmed again by the study of Lo et al.71. So, the high-
resolution EUS miniprobe was found to be able to visu-
alize the intramural, paraesophageal and periesophageal
vascular structures in detail, as well as to demonstrate the
therapeutic effect of EIS and EBL43. The diameter of
perforating veins was found to positively correlate with the
presence of red spots and grade of esophageal varices.
Periesophageal veins were more common in patients with
high-grade varices and red spots. Patients in whom per-
forating and periesophageal veins disappeared after EIS
were observed to have a low risk of variceal recurrence. On
the other hand, patients who underwent EBL therapy
were found to have persistent perforating and periesoph-
ageal veins even after eradication, which could explain the
high recurrence rates observed with this treatment mo-
dality. The authors give the opinion that the exact visual-
ization of the collateral circulation could be a prerequisite
for the eradication of varices and might help predict in-
appropriate endoscopic treatment or recurrence. However,
further investigations of this new diagnostic approach are
required to determine whether these observations will
have an impact on the management of variceal bleeding,
particularly in choosing among different modalities.
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SAÆETAK
ENDOSKOPSKO LIJE»ENJE KRVARENJA IZ GASTROEZOFAGUSNIH VARIKOZITETA
N. LjubiËiÊ i M. ©pero
Prikazane su suvremene moguÊnosti endoskopskog lijeËenja krvarenja iz gastroezofagusnih varikoziteta. Dva su glavna
naËina endoskopskog lijeËenja gastroezofagusnih varikoziteta: endoskopska injekcijska skleroterapija i endoskopska ligacija
varikoziteta. Endoskopska skleroterapija i ligacija varikoziteta kao samostalne metode podjednako su uËinkovite u zaustavljanju
akutnog krvarenja iz varikoziteta, no endoskopska ligacija varikoziteta bolja je metoda u odnosu na skleroterapiju jer se njome
obliteracija varikoziteta postiæe bræe i u manjem broju tretmana te s manjim brojem komplikacija. Glede kombinacije ligacije
i skleroterapije, inicijalna ligacija, a potom postupci skleroterapije kad podvezani varikoziteti postanju manji, vjerojatno je
prikladniji postupak za sigurno i dugotrajno iskorjenjivanje varikoziteta. Obliteracija varikoziteta Histoacrylom jedini je potvrðen
i djelotvoran naËin endoskopskog lijeËenja varikoziteta æeluca. Upotreba endoskopskih klipsa kao samostalan naËin lijeËenja jo¹
uvijek nije preporuËljiva. Uloga endoskopskog ultrazvuka u procjeni portalne hipertenzije raste, a isti moæe steÊi ulogu u
odabiru najboljeg pristupa lijeËenju svakog bolesnika pojedinaËno.
KljuËne rijeËi: Ezofagusni i æeluËani varikoziteti, terapija; Gastrointestinalno krvarenje, terapija; Endoskopija, probavni sustav
